Role of lipid nanocarriers for enhancing oral absorption and bioavailability of insulin and GLP-1 receptor agonists

Poudwal, Swapna; Misra, Ambikanandan; Shende, Pravin

doi:10.1080/1061186x.2021.1894434

Cited by 12 publications

(3 citation statements)

References 128 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This was probably a result of the difference in the HbA1c‐lowering effect observed across the two studies, although a difference in the mechanism of action of ORMD‐0801 may also have been responsible for this. Numerous approaches to create oral insulin have been reported in recent years, but to the best of our knowledge, all are in early preclinical or clinical stages of development (including utilization of microparticles, microcapsules and microspheres, use of protease inhibitors, lipid nanocarriers, protein‐stabilized multiple emulsion with permeation enhancers, nanocomposite system of organoclay/glycol chitosan/Eudragit([R])S100, inclusion complex based on N‐acetyl‐L‐cysteine and arginine‐modified hydroxypropyl‐beta‐cyclodextrin, virus‐mimicking polyelectrolyte complexes and Zein‐based nanocarriers, amongst others) 19‐27 …”

Section: Discussionmentioning

confidence: 99%

“…Numerous approaches to create oral insulin have been reported in recent years, but to the best of our knowledge, all are in early preclinical or clinical stages of development (including utilization of microparticles, microcapsules and microspheres, use of protease inhibitors, lipid nanocarriers, protein-stabilized multiple emulsion with permeation enhancers, nanocomposite system of organoclay/glycol chitosan/Eudragit([R])S100, inclusion complex based on N-acetyl-L-cysteine and arginine-modified hydroxypropylbeta-cyclodextrin, virus-mimicking polyelectrolyte complexes and Zein-based nanocarriers, amongst others). [19][20][21][22][23][24][25][26][27] The strengths of the current study include its randomized, double-blind design and comparatively large sample size. Its limitations include the short washout period, the comparatively short exposure period and lack of ORMD-0801 dose titration.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and safety of 28‐day treatment with oral insulin (ORMD‐0801) in patients with type 2 diabetes: A randomized, placebo‐controlled trial

Eldor

Neutel

Homer³

et al. 2021

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

Aim To assess the safety and efficacy of oral insulin (ORMD‐0801) in patients with type 2 diabetes (T2D). Materials and Methods After a 2‐week washout of other medications, adult metformin‐treated patients with T2D were randomized to receive placebo or 16 or 24 mg ORMD‐0801, once daily, at bedtime, for 28 days. The mean change from baseline weighted mean night‐time glucose levels was determined from 2 nights of continuous glucose monitoring (CGM) recordings during the placebo run‐in and last week of treatment. Results In total, 188 patients (HbA1c: 7.82% ± 0.88% [placebo] and 8.08% ± 1.11% [pooled ORMD‐0801 group]) were enrolled. In the placebo group, mean night‐time CGM increased from baseline by 13.7 ± 26.1 mg/dL, whereas the increase was significantly smaller in the pooled ORMD‐0801 group (1.7 ± 23.5 mg/dL, P = .0120). Glycaemic control variables (24‐hour, fasting and daytime CGM glucose) also displayed smaller increases with ORMD‐0801 versus placebo. Change from baseline HbA1c was −0.01% in the pooled ORMD‐0801 group versus +0.20% in the placebo group (P = .0149). ORMD‐0801 was well tolerated, with similar adverse event and hypoglycaemia rates as placebo. Conclusions In patients with T2D, bedtime ORMD‐0801 curbed increases in night‐time glycaemia, 24‐hour glycaemia and HbA1c, without increasing the risk of hypoglycaemia or safety events compared with the control arm.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of 28‐day treatment with oral insulin (ORMD‐0801) in patients with type 2 diabetes: A randomized, placebo‐controlled trial

Eldor

Neutel

Homer³

et al. 2021

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

“…Applying polymers’ combinations and different strategies improves the stability of the hydrophilic drug in the lipophilic core. In addition, high entrapment efficiency and easy scalability were necessary to develop an inexpensive, non-invasive drug delivery system [ 121 , 122 ].…”

Section: Mechanism Of Lipid-based Drug Delivery Systemsmentioning

confidence: 99%

Combinational System of Lipid-Based Nanocarriers and Biodegradable Polymers for Wound Healing: An Updated Review

Far

Naimi-Jamal

Sedaghat

et al. 2023

JFB

View full text Add to dashboard Cite

Skin wounds have imposed serious socioeconomic burdens on healthcare providers and patients. There are just more than 25,000 burn injury-related deaths reported each year. Conventional treatments do not often allow the re-establishment of the function of affected regions and structures, resulting in dehydration and wound infections. Many nanocarriers, such as lipid-based systems or biobased and biodegradable polymers and their associated platforms, are favorable in wound healing due to their ability to promote cell adhesion and migration, thus improving wound healing and reducing scarring. Hence, many researchers have focused on developing new wound dressings based on such compounds with desirable effects. However, when applied in wound healing, some problems occur, such as the high cost of public health, novel treatments emphasizing reduced healthcare costs, and increasing quality of treatment outcomes. The integrated hybrid systems of lipid-based nanocarriers (LNCs) and polymer-based systems can be promising as the solution for the above problems in the wound healing process. Furthermore, novel drug delivery systems showed more effective release of therapeutic agents, suitable mimicking of the physiological environment, and improvement in the function of the single system. This review highlights recent advances in lipid-based systems and the role of lipid-based carriers and biodegradable polymers in wound healing.

show abstract

Ionic liquids: a state of the art for biomedical applications

Gandhewar

Shende

2021

Ionics

View full text Add to dashboard Cite

Role of lipid nanocarriers for enhancing oral absorption and bioavailability of insulin and GLP-1 receptor agonists

Cited by 12 publications

References 128 publications

Efficacy and safety of 28‐day treatment with oral insulin (ORMD‐0801) in patients with type 2 diabetes: A randomized, placebo‐controlled trial

Efficacy and safety of 28‐day treatment with oral insulin (ORMD‐0801) in patients with type 2 diabetes: A randomized, placebo‐controlled trial

Combinational System of Lipid-Based Nanocarriers and Biodegradable Polymers for Wound Healing: An Updated Review

Ionic liquids: a state of the art for biomedical applications

Contact Info

Product

Resources

About